Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

August 31, 2012

Study Completion Date

November 30, 2012

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Lenalidomide, Decitabine

Decitabine 20mg/m2 over one hour IV for 5 days, with cycles repeated every 28 days. Lenalidomide given orally on Days 1-21 followed by 7 days of rest at various dose escalated cohorts (5 mg, 10mg, 15mg, 20 mg, 25 mg)

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Duke University

OTHER